|
|||||
|
|
PER.C6 cells as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated poliovirus vaccine |
|
| Authors: | Barbara P. Sanders Diana Edo-Matas Jerome H.H.V. Custers Martin H. Koldijk Vincent Klaren Marije Turk Alfred Luitjens Wilfried A.M. Bakker Fons Uytdehaag Jaap Goudsmit John A. Lewis Hanneke Schuitemaker |
| Affiliation: | 1. Crucell Holland BV, Archimedesweg 4-6, 2333 CN Leiden, The Netherlands;2. Batavia Bioservices BV, Leiden, Zernikedreef 9, 2333 CK Leiden, The Netherlands;3. National Institute for Public Health and the Environment (RIVM), Vaccinology Unit, Process Development Department, P.O. Box 1, 3720 BA Bilthoven, The Netherlands |
| Abstract: | There are two highly efficacious poliovirus vaccines: Sabin's live-attenuated oral polio vaccine (OPV) and Salk's inactivated polio vaccine (IPV). OPV can be made at low costs per dose and is easily administrated. However, the major drawback is the frequent reversion of the OPV vaccine strains to virulent poliovirus strains which can result in Vaccine Associated Paralytic Poliomyelitis (VAPP) in vaccinees. Furthermore, some OPV revertants with high transmissibility can circulate in the population as circulating Vaccine Derived Polioviruses (cVDPVs). IPV does not convey VAPP and cVDPVs but the high costs per dose and insufficient supply have rendered IPV an unfavorable option for low and middle-income countries. |
| Keywords: | Poliovirus PER.C6® cells Vaccine IPV Poliomyelitis |
| 本文献已被 ScienceDirect 等数据库收录！ | |